157 related articles for article (PubMed ID: 18795290)
1. Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Xu Y; Kolesar JM; Schaaf LJ; Drengler R; Duan W; Otterson G; Shapiro C; Kuhn J; Villalona-Calero MA
Cancer Chemother Pharmacol; 2009 May; 63(6):1073-82. PubMed ID: 18795290
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Villalona-Calero M; Schaaf L; Phillips G; Otterson G; Panico K; Duan W; Kleiber B; Shah M; Young D; Wu WH; Kuhn J
Cancer Chemother Pharmacol; 2007 Jan; 59(1):23-33. PubMed ID: 16685529
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Argiris A; Kut V; Luong L; Avram MJ
Invest New Drugs; 2006 May; 24(3):203-12. PubMed ID: 16096702
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Mrozek E; Kolesar J; Young D; Allen J; Villalona-Calero M; Shapiro CL
Ann Oncol; 2008 Aug; 19(8):1417-1422. PubMed ID: 18407955
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Tolcher AW; LoRusso P; Arzt J; Busman TA; Lian G; Rudersdorf NS; Vanderwal CA; Waring JF; Yang J; Holen KD; Rosen LS
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1041-9. PubMed ID: 26429709
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
Javle MM; Cao S; Durrani FA; Pendyala L; Lawrence DD; Smith PF; Creaven PJ; Noel DC; Iyer RV; Rustum YM
Clin Cancer Res; 2007 Feb; 13(3):965-71. PubMed ID: 17289892
[TBL] [Abstract][Full Text] [Related]
8. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Yamao T; Shirao K; Matsumura Y; Muro K; Yamada Y; Goto M; Chin K; Shimada Y
Ann Oncol; 2001 Dec; 12(12):1729-35. PubMed ID: 11843251
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer.
Dy GK; Mandrekar S; Peethambaram PP; Okuno SH; Croghan GC; Hanson LJ; Furth A; Adjei AA
Cancer Chemother Pharmacol; 2005 Dec; 56(6):623-8. PubMed ID: 15999272
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
12. Mitomycin as a modulator of irinotecan anticancer activity.
Villalona-Calero MA; Kolesar JM
Oncology (Williston Park); 2002 Aug; 16(8 Suppl 7):21-5. PubMed ID: 12199629
[TBL] [Abstract][Full Text] [Related]
13. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
El-Rayes BF; Zalupski MM; Manza SG; Rusin B; Ferris AM; Vaishampayan U; Heilbrun LK; Venkatramanamoorthy R; Shields AF; Philip PA
Cancer Chemother Pharmacol; 2008 Feb; 61(2):283-9. PubMed ID: 17429629
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Maiello E; Giuliani F; Gebbia V; Di Renzo N; Pezzella G; Romito S; Mallamaci R; Lopez M; Colucci G;
Ann Oncol; 2006 Jun; 17 Suppl 7():vii55-9. PubMed ID: 16760295
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Sayar H; Shen Z; Lee SJ; Royce M; Rabinowitz I; Lee F; Smith H; Eberhardt S; Maestas A; Lu H; Verschraegen C
Invest New Drugs; 2009 Apr; 27(2):153-8. PubMed ID: 18773144
[TBL] [Abstract][Full Text] [Related]
16. A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.
Fakih MG; Pendyala L; Smith PF; Creaven PJ; Reid ME; Badmaev V; Azrak RG; Prey JD; Lawrence D; Rustum YM
Clin Cancer Res; 2006 Feb; 12(4):1237-44. PubMed ID: 16489079
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Saif MW; Sellers S; Li M; Wang W; Cusimano L; Wang H; Zhang R
Cancer Chemother Pharmacol; 2007 Nov; 60(6):871-82. PubMed ID: 17345085
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Malik I; Hussein F; Bush D; Alqaisi M; Bernal P; Byrd J; Garberoglio C
Am J Clin Oncol; 2010 Jun; 33(3):242-5. PubMed ID: 19806036
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
